M.R. Mattiacci

658 total citations
10 papers, 519 citations indexed

About

M.R. Mattiacci is a scholar working on Oncology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, M.R. Mattiacci has authored 10 papers receiving a total of 519 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Genetics and 3 papers in Pathology and Forensic Medicine. Recurrent topics in M.R. Mattiacci's work include Estrogen and related hormone effects (3 papers), Cancer Treatment and Pharmacology (3 papers) and Reproductive Physiology in Livestock (2 papers). M.R. Mattiacci is often cited by papers focused on Estrogen and related hormone effects (3 papers), Cancer Treatment and Pharmacology (3 papers) and Reproductive Physiology in Livestock (2 papers). M.R. Mattiacci collaborates with scholars based in Switzerland, Germany and Netherlands. M.R. Mattiacci's co-authors include Jayanthi Savio, M. Drost, W.W. Thatcher, KW Entwistle, Robert Paridaens, P. Therasse, Martine Piccart, Luc Dirix, L.V.A.M. Beex and K. J. Roozendaal and has published in prestigious journals such as Journal of Clinical Oncology, European Journal of Cancer and Reproduction.

In The Last Decade

M.R. Mattiacci

10 papers receiving 486 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M.R. Mattiacci Switzerland 7 369 286 148 104 100 10 519
Megan Minten United States 7 216 0.6× 374 1.3× 21 0.1× 209 2.0× 46 0.5× 10 589
M. Glaucia Teixeira United States 6 72 0.2× 207 0.7× 89 0.6× 53 0.5× 21 0.2× 8 347
Karin J. Dawson United Kingdom 10 71 0.2× 51 0.2× 26 0.2× 227 2.2× 16 0.2× 16 424
Xing Su China 9 132 0.4× 5 0.0× 139 0.9× 14 0.1× 83 0.8× 15 360
J.J. Lim South Korea 7 25 0.1× 21 0.1× 37 0.3× 74 0.7× 32 0.3× 10 219
Zi-Ming Zhao United States 7 44 0.1× 19 0.1× 74 0.5× 6 0.1× 114 1.1× 12 238
York Hunt Ng Canada 5 27 0.1× 27 0.1× 9 0.1× 71 0.7× 110 1.1× 5 481
Caterina Clementi United States 8 46 0.1× 24 0.1× 13 0.1× 146 1.4× 28 0.3× 11 488
Meena Verma India 6 22 0.1× 10 0.0× 234 1.6× 38 0.4× 12 0.1× 15 391

Countries citing papers authored by M.R. Mattiacci

Since Specialization
Citations

This map shows the geographic impact of M.R. Mattiacci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.R. Mattiacci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.R. Mattiacci more than expected).

Fields of papers citing papers by M.R. Mattiacci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.R. Mattiacci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.R. Mattiacci. The network helps show where M.R. Mattiacci may publish in the future.

Co-authorship network of co-authors of M.R. Mattiacci

This figure shows the co-authorship network connecting the top 25 collaborators of M.R. Mattiacci. A scholar is included among the top collaborators of M.R. Mattiacci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.R. Mattiacci. M.R. Mattiacci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Connor, Joseph P., Mihaela Cristea, Nancy Lewis, et al.. (2013). A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors. BMC Cancer. 13(1). 20–20. 35 indexed citations
2.
Gillessen, Silke, Ulrike Gnad-Vogt, Elisa Gallerani, et al.. (2012). A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. European Journal of Cancer. 49(1). 35–44. 45 indexed citations
3.
Falchook, Gerald S., Siqing Fu, David S. Hong, et al.. (2011). 1245 POSTER Phase I Dose-escalation Study of the Oral Selective C-Met Inhibitor EMD 1204831 in Patients With Advanced Solid Tumours. European Journal of Cancer. 47. S158–S158. 3 indexed citations
4.
Connor, Joseph P., Roger Stupp, Mihaela Cristea, et al.. (2011). Phase IB trial of EMD 273066 (huKS-IL2) with cyclophosphamide in patients with EpCAM-positive advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 2556–2556. 2 indexed citations
5.
6.
Paridaens, Robert, P. Therasse, Luc Dirix, et al.. (2004). First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. Journal of Clinical Oncology. 22(14_suppl). 515–515. 82 indexed citations
7.
Paridaens, Robert, P. Therasse, Luc Dirix, et al.. (2004). First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC Breast Group. Journal of Clinical Oncology. 22(14_suppl). 515–515. 31 indexed citations
8.
Paridaens, Robert, Emiel J. Rutgers, R. Coleman, et al.. (2004). Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901. European Journal of Cancer Supplements. 2(3). 70–70. 4 indexed citations
9.
10.
Savio, Jayanthi, M.P. Boland, Niamh Hynes, M.R. Mattiacci, & J Roche. (1990). Will the first dominant follicle of the estrous cycle of heifers ovulate following luteolysis on day 7?. Theriogenology. 33(3). 677–687. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Megan Minten Breakdown of academic impact, for papers by M. Glaucia Teixeira Breakdown of academic impact, for papers by Karin J. Dawson Breakdown of academic impact, for papers by Xing Su Breakdown of academic impact, for papers by J.J. Lim Breakdown of academic impact, for papers by Zi-Ming Zhao Breakdown of academic impact, for papers by York Hunt Ng Breakdown of academic impact, for papers by Caterina Clementi Breakdown of academic impact, for papers by Meena Verma
Rankless by CCL
2026